Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an efavirenz-based regimen

Clinical Infectious Diseases

Volumn 52, Issue 4, 2011, Pages 547-550

  Lartey, Margaret ^a   Sagoe, Kwamena W ^a   Yang, Hongmei ^c   Kenu, Ernest ^b   Xexemeku, Fafa ^b   Oliver Commey, Joseph ^b   Boima, Vincent ^b   Seshie, Markafui ^a   Sagoe, Augustine ^b   Mingle, Julius A A ^a   Flanigan, Timothy P ^d   Wu, Hulin ^c   Kwara, Awewura ^d  

^a UNIVERSITY OF GHANA   (Ghana)

^b KORLE BU TEACHING HOSPITAL   (Ghana)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; BENZOXAZINES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; TUBERCULOSIS; VIRAL LOAD; VIREMIA;

EID: 79951841208     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq196     Document Type: Article

References (26)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009426 2010. http://whqlibdoc. who.int/publications/2009/9789241598866-eng.pdf. Accessed 26 August 2010.
2. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
3. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004;190:1670-6. (Pubitemid 39411018)
4. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-6. (Pubitemid 44306486)
5. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50:148-52.
6. Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005;26:283-94, vi-vii.
7. Kalou M, Sassan-Morokro M, Abouya L, et al. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire. J Med Virol 2005;75:202-8. (Pubitemid 40053729)
8. Morris L, Martin DJ, Bredell H, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis 2003;187:1967-71. (Pubitemid 36724497)
9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
10. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12: F111-5. (Pubitemid 28330713)
11. Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triplenucleoside or efavirenz-containing regimens: ACTG A5166 s. J Infect Dis 2007;195:1169-76. (Pubitemid 46543448)
12. Polis MA, Sidorov IA, Yoder C, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001;358:1760-5. (Pubitemid 33153000)
13. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999;179:799-807. (Pubitemid 29159324)
14. Wu H, Lathey J, Ruan P, et al. Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis 2004;189:593-601. (Pubitemid 38270911)
15. Rezk NL, Crutchley RD, Yeh RF, Kashuba AD. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit 2006;28:517-25. (Pubitemid 44181485)
16. Wu H, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999;55:410-8. (Pubitemid 29302563)
17. Ding AA, Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2001;2:13-29.
18. Wu H, Ding AA, De Gruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS 1999;13:429-30. (Pubitemid 29095112)
19. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003;187:896-900. (Pubitemid 36337901)
20. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006;193:1437-40. (Pubitemid 43673392)
21. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003;17:2615-22.
22. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006;58:1299-302. (Pubitemid 44884158)
23. Ren Y, Nuttall JJ, Eley BS, et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009;50:439-43.
24. *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009;67:427-36.
25. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20:1605-12. (Pubitemid 44162402)
26. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-25.